To our knowledge, there is only one previously published case report of response to BRAF-targeted therapy in RDD, which describes the clinical and radiological response to the BRAF inhibitor dabrafenib in a pediatric patient with mixed Langerhans cell histiocytosis and RDD harboring a BRAF V600E mutation (10). Here, BRAF is linked to Langerhans cell histiocytosis.